Figure 1.

Western Blot Analysis for various SMC markers of M3 cell linesubjected to different differentiation medium (DM) treatments. hBM-MSCs were plated onto fibronectin-coated T175 flasks and treated for four days with DM, DM with all-trans retinoic acid (DM + atRA), DM with platelet-derived growth factor-BB (DM + PDGF), and DM with PDGF and transforming growth factor-β1 (DM + PDGF + TGFB1), respectively. Western blot analysis was performed for smooth muscle cell markers (A) SM22-α, caldesmon, and smooth muscle myosin heavy chain-11 (MYH11). Fold change was determined with respect to DM treatment (B). The treatment (DM + PDGF + TGFB1) showed a statistically significant increase in MYH11 (B) expression (*-p-value < 0.05).